Pentanucleotide repeat polymorphism, lipoprotein(a) levels, and risk of ischemic heart disease

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 10, 2008, Pages 3769-3776

  Kamstrup, Pia R ^a   Tybjærg Hansen, Anne ^b,c   Steffensen, Rolf ^d   Nordestgaard, Børge G ^a,c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; LIPOPROTEIN A;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE REPEAT; PRIORITY JOURNAL;

EID: 53749088453     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-0830     Document Type: Article

References (25)

1. Utermann G 2006 Lipoprotein(a). In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, Medical Publishing Division; 2753-2787
2. Danesh J, Collins R, Peto R 2000 Lipoprotein(a) and coronary heart disease-meta-analysis of prospective studies. Circulation 102:1082-1085
3. Ariyo AA, Thach C, Tracy R 2003 Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med 349:2108-2115
4. Luc G, Bard JM, Arveiler D, Ferrieres J, Evans A, Amouyel P, Fruchart JC, Ducimetiere P 2002 Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis 163:377-384
5. Rifai N, Ma J, Sacks FM, Ridker PM, Hernandez WJ, Stampfer MJ, Marcovina SM 2004 Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: The Physicians' Health Study. Clin Chem 50:1364-1371
6. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W 2001 Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104:1108-1113
7. Danik JS, Rifai N, Buring JE, Ridker PM 2006 Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA 296:1363-1370
8. von Eckardstein A, Schulte H, Cullen P, Assmann G 2001 Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 37:434-439
9. Kamstrup PR, Benn M, Tybjærg-Hansen A, Nordestgaard BG 2008 Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 117:176-184
10. Trommsdorff M, Kochl S, Lingenhel A, Kronenberg F, Delport R, Vermaak H, Lemming L, Klausen IC, Faergeman O, Utermann G 1995 A pentanucleotide repeat polymorphism in the 5′ control region of the apolipoprotein(a) gene is associated with lipoprotein(a) plasma concentrations in Caucasians. J Clin Invest 96:150-157
11. Rosby O, Berg K 2000 LPA gene: interaction between the apolipoprotein(a) size ('kringle IV' repeat) polymorphism and a pentanucleotide repeat polymorphism influences Lp(a) lipoprotein level. J Intern Med 247:139-152
12. Holmer SR, Hengstenberg C, Kraft HG, Mayer B, Poll M, Kurzinger S, Fischer M, Lowel H, Klein G, Riegger GA, Schunkert H 2003 Association of polymorphisms of the apolipoprotein(a) gene with lipoprotein(a) levels and myocardial infarction. Circulation 107:696-701
13. Brazier L, Tiret L, Luc G, Arveiler D, Ruidavets JB, Evans A, Chapman J, Cambien F, Thillet J 1999 Sequence polymorphisms in the apolipoprotein(a) gene and their association with lipoprotein(a) levels and myocardial infarction. The ECTIM Study. Atherosclerosis 144:323-333
14. Amemiya H, Arinami T, Kikuchi S, Yamakawa-Kobayashi K, Li L, Fujiwara H, Hiroe M, Marumo F, Hamaguchi H 1996 Apolipoprotein(a) and pentanucleotide repeat polymorphisms are associated with the degree of atherosclerosis in coronary heart disease. Atherosclerosis 123:181-191
15. Valenti K, Aveynier E, Leaute S, Laporte F, Hadjian AJ 1999 Contribution of apolipoprotein(a) size, pentanucleotide TTTTA repeat and C/T(+93) polymorphisms of the apo(a) gene to regulation of lipoprotein(a) plasma levels in a population of young European Caucasians. Atherosclerosis 147:17-24
16. Nordestgaard BG, Benn M, Schnohr P, Tybjærg-Hansen A 2007 Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298:299-308
17. Schnohr P, Jensen JS, Scharling H, Nordestgaard BG 2002 Coronary heart disease risk factors ranked by importance for the individual and community. A 21-year follow-up of 12,000 men and women from The Copenhagen City Heart Study. Eur Heart J 23:620-626
18. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R 1999 Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 150:341-353
19. Boffa MB, Marcovina SM, Koschinsky ML 2004 Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem 37:333-343
20. Deb A, Caplice NM 2004 Lipoprotein(a): new insights into mechanisms of atherogenesis and thrombosis. Clin Cardiol 27:258-264
21. Nielsen LB, Grønholdt ML, Schrøder TV, Stender S, Nordestgaard BG 1997 In vivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima. Arterioscler Thromb Vasc Biol 17:905-911
22. Nielsen LB, Juul K, Nordestgaard BG 1998 Increased degradation of lipoprotein(a) in atherosclerotic compared with nonlesioned aortic intima-inner media of rabbits: in vivo evidence that lipoprotein(a) may contribute to foam cell formation. Arterioscler Thromb Vasc Biol 18:641-649
23. Bopp S, Kochl S, Acquati F, Magnaghi P, Petho-Schramm A, Kraft HG, Utermann G, Muller HJ, Taramelli R 1995 Ten allelic apolipoprotein[a] 5′ flanking fragments exhibit comparable promoter activities in HepG2 cells. J Lipid Res 36:1721-1728
24. Kronenberg F, Kronenberg MF, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, Egger G, Utermann G, Willeit J 1999 Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 100:1154-1160
25. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ 1995 Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 274:1771-1774